PCSA Stock Forecast: Processa Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 21 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Processa Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (59): Reported profit is backed by cash, and the company is not expanding recklessly.
Momentum (7): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PCSA stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PCSA, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 19 most recent actions, 0 moved their price target up and 4 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 2 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | $2.00 → $1.00 |
| 30 June 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 5 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 3 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | $6.00 |
| 20 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Aug 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 1 Aug 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 12 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Apr 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 6 Mar 2024 | Benchmark | Reiterates | Speculative Buy | — |
| 17 Nov 2023 | Maxim Group | Downgrade | Hold | — |
| 4 Apr 2023 | Benchmark | Maintains | Speculative Buy | $9.00 → $4.00 |
| 3 Apr 2023 | Oppenheimer | Maintains | Outperform | $5.00 → $3.00 |
| 12 Jan 2023 | Maxim Group | Maintains | Buy | $9.00 → $5.00 |
| 19 Apr 2022 | Maxim Group | Initiates | Buy | $9.00 |
| 3 Aug 2021 | Oppenheimer | Initiates | Outperform | — |
| 2 Aug 2021 | Oppenheimer | Initiates | Outperform | — |
| 28 Oct 2020 | Craig-Hallum | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
PCSA appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PCSA vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Processa Pharmaceuticals, Inc. returned −77.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PCSA analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- —
- EV / EBITDA
- —
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- —
- Return on assets
- −10.2%
- Dividend yield
- —
Higher than 26% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Processa Pharmaceuticals, Inc. has a market value of $4.7M and an enterprise value of $186.1M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$13.4M.
Free cash flow in the twelve months to 30 June 2026: −$13.3M.
Processa Pharmaceuticals, Inc. spent $320.0 on share buybacks in the twelve months to 30 June 2026.
Processa Pharmaceuticals, Inc. employs 12 people.
Data provided by Twelve Data
PCSA and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PCSA’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Processa Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PCSA
How does Ticker Nerd's model rank PCSA?
As at 21 Nov 2026, Processa Pharmaceuticals, Inc. ranks 21 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (59 of 100).
What is the PCSA stock forecast for 2030?
No analyst covering Processa Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PCSA are extrapolating price history, which says nothing about the business.
How has PCSA stock performed over the past year?
Processa Pharmaceuticals, Inc. returned -77.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Processa Pharmaceuticals, Inc. do?
Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy and other therapies for serious diseases with high unmet medical needs. The company’s current portfolio centers on oncology programs designed to improve the safety and efficacy of existing cancer treatments by modifying how approved drugs are metabolized and distributed while preserving their cancer-killing mechanisms.
About Processa Pharmaceuticals, Inc.
Processa Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation chemotherapy and other therapies for serious diseases with high unmet medical needs. The company’s current portfolio centers on oncology programs designed to improve the safety and efficacy of existing cancer treatments by modifying how approved drugs are metabolized and distributed while preserving their cancer-killing mechanisms. Its pipeline also includes non-oncology candidates for conditions such as gastroparesis and glomerular disease. Processa Pharmaceuticals uses a regulatory science-driven approach to advance drug candidates that aim to offer better treatment options for patients facing complex medical conditions. Headquartered in Vero Beach, Florida, Processa Pharmaceuticals participates in the broader pharmaceutical innovation market through research, clinical development, and product pipeline advancement.
CEO Mr. George K. Ng Esq., J.D. · 12 employees · United States · https://www.processapharmaceuticals.com